Fintel reports that on August 10, 2023, Citigroup maintained coverage of Merus N.V (NASDAQ:MRUS) with a Buy recommendation.
Analyst Price Forecast Suggests 103.11% Upside
As of August 2, 2023, the average one-year price target for Merus N.V is 46.51. The forecasts range from a low of 35.35 to a high of $51.45. The average price target represents an increase of 103.11% from its latest reported closing price of 22.90.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Merus N.V is 41MM, an increase of 0.05%. The projected annual non-GAAP EPS is -3.45.
What is the Fund Sentiment?
There are 169 funds or institutions reporting positions in Merus N.V. This is an increase of 14 owner(s) or 9.03% in the last quarter. Average portfolio weight of all funds dedicated to MRUS is 0.57%, an increase of 14.91%. Total shares owned by institutions increased in the last three months by 2.99% to 39,062K shares. 
The put/call ratio of MRUS is 1.13, indicating a bearish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 3,137K shares representing 6.30% ownership of the company. In it's prior filing, the firm reported owning 3,690K shares, representing a decrease of 17.63%. The firm decreased its portfolio allocation in MRUS by 0.07% over the last quarter.
Bvf holds 2,978K shares representing 5.98% ownership of the company. No change in the last quarter.
Commodore Capital holds 2,950K shares representing 5.92% ownership of the company. In it's prior filing, the firm reported owning 2,733K shares, representing an increase of 7.37%. The firm increased its portfolio allocation in MRUS by 29.72% over the last quarter.
Federated Hermes holds 2,639K shares representing 5.30% ownership of the company. In it's prior filing, the firm reported owning 3,924K shares, representing a decrease of 48.72%. The firm decreased its portfolio allocation in MRUS by 60.04% over the last quarter.
Deerfield Management Company, L.p. holds 2,380K shares representing 4.78% ownership of the company. No change in the last quarter.
Merus N.V Background Information
(This description is provided by the company.)
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
Additional reading:
- Employment Agreement, dated as of June 14, 2023, by and between Merus US, Inc. and Gregory D. Perry.
- Employment Agreement, dated February 24, 2023, by and among Merus US, Inc., the Registrant and Hui Liu
- DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
- Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentat
- Employment Agreement, dated January 1, 2023, by and between Merus US, Inc. and Peter Silverman
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
